Revisiting the use of pioglitazone in the treatment of type 2 diabetes

Endocrine Practice

Volumn 22, Issue 11, 2016, Pages 1343-1346

  Einhorn, Daniel ^a   Fonseca, Vivian ^b  

^a Whittier Institute for Diabetes   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE;

DIABETES MELLITUS, TYPE 2; HUMAN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 85020727559     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP161409.CO     Document Type: Note

References (15)

1. Fonseca VA. Early identification and treatment of insulin resistance: Impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone. 2007;8 Suppl 7:S7-S18.
2. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351:1106-1118.
3. Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240-249.
4. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract. 2016;22:84-113.
5. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265-277.
6. Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: Population based cohort study. BMJ. 2016;352:i1541.
7. Toprani A, Fonseca V. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab. 2011;13:276-280.
8. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
9. Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord. 2006;4:179-184.
10. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517-522.
11. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
12. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): A randomised controlled trial. Lancet. 2005;366:1279-1289.
13. Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone clinical trial in macro vascular events (PROactive 10). Am Heart J. 2008;155:712-717.
14. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321-1331.
15. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Ann Intern Med. 2016;165:305-315.